<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557997</url>
  </required_header>
  <id_info>
    <org_study_id>6074</org_study_id>
    <nct_id>NCT02557997</nct_id>
  </id_info>
  <brief_title>Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation</brief_title>
  <official_title>Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim at comparing markers of HIV reservoir, monocyte function and immune activation between
      antiretroviral therapy (ART)-naïve (chronic infection or primary infection), ART-controlled
      or ART-failing HIV infected adults initiating a dolutegravir (DTG)-based regimen. The
      investigators' purpose is to measure cell associated HIV-1 DNA, monocyte function [soluble
      CD14 (sCD14), soluble CD163 (sCD163)], and immune activation [neopterine, interleukin-6
      (IL-6) and high-sensitivity C-reactive protein (hsCRP)] biomarkers at different time points
      between baseline and week 48 post DTG-based regimen initiation in each group.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Proviral HIV-1 DNA at Week 48</measure>
    <time_frame>Baseline and 48 weeks post DTG-based regimen initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of biomarkers of immune activation</measure>
    <time_frame>Baseline, 24 and 48 weeks post DTG-based regimen initiation</time_frame>
    <description>Soluble CD14 (sCD14), soluble CD163 (sCD163), neopterine, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">202</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>ART-naive (primary infection)</arm_group_label>
    <description>ART-naive (primary infection) HIV infected adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART-naïve (chronic infection)</arm_group_label>
    <description>ART-naïve (chronic infection) HIV infected adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART-controlled</arm_group_label>
    <description>ART-controlled HIV infected adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART-failing</arm_group_label>
    <description>ART-failing HIV infected adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood tube bottom analyses</intervention_name>
    <arm_group_label>ART-naive (primary infection)</arm_group_label>
    <arm_group_label>ART-naïve (chronic infection)</arm_group_label>
    <arm_group_label>ART-controlled</arm_group_label>
    <arm_group_label>ART-failing</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients visiting an HIV Infection care center at a university hospital will be selected
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged from de 18 to 80 years

          -  Patient starting a DTG-regimen

          -  Patients agreeing to use methods of birthcontrol while on the study and during the 6
             weeks after stopping DTG treatment

          -  Signed and dated written informed consent is obtained from the subject or the
             subject's legal representative prior to screening

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  HBV or HCV coinfection

          -  Participation in another clinical drug or device trial where the last dose of drug was
             within the past 30 days or an investigational medical device is currently implanted

          -  Documented resistance to DTG

          -  Allergy or intolerance to the study drugs or their components or drugs of their class

          -  Any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4
             lipids) at Screening.

          -  Coadministration with Dofelitide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samira FAFI-KREMER, PhD</last_name>
    <email>samira.fafi-kremer@unistra.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre GANTNER, PhD</last_name>
    <email>pierre.gantner@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Trait d'Union</name>
      <address>
        <city>STRASBOURG Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David REY, MD</last_name>
      <email>david.rey@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV reservoir</keyword>
  <keyword>HIV-1 DNA</keyword>
  <keyword>Immune activation</keyword>
  <keyword>Monocyte function</keyword>
  <keyword>Activation biomarkers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

